Rarecells Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $13M

  • Investors
  • 3

Rarecells General Information

Description

Developer of a biotechnology platform designed to facilitate early-stage detection of cancer using circulating tumor cells. The company's platform conducts circulating tumor cell tests on a given blood sample, analyzes gradual cell growth, tracks serum secretion markers, abnormal and rapid multiplication of biomolecules and protein cells, and sends signals when a high number of circulating non-tumor epithelial cells is released into the blood, enabling medical institutions to offer alternative cancer treatment therapies that are non-invasive, painless, and cheap.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Alexandria LaunchLabs-Columbia, 3960 Broadway
  • 6th Floor
  • New York, NY 10032
  • United States
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Alexandria LaunchLabs-Columbia, 3960 Broadway
  • 6th Floor
  • New York, NY 10032
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rarecells Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC (Series A) 09-Dec-2021 $13M Completed Generating Revenue
To view Rarecells’s complete valuation and funding history, request access »

Rarecells Patents

Rarecells Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024398398-A1 Screening samples for subclinical indicia of cancer Pending 14-Dec-2023
EP-4824278-A1 Screening samples for subclinical indicia of cancer Pending 14-Dec-2023
WO-2025129182-A1 Screening samples for subclinical indicia of cancer Inactive 14-Dec-2023
WO-2024259369-A1 Compositions targeting giant cells in blood disorders Inactive 14-Jun-2023
US-20260227409-A1 Distinctive identification and use of a liquid biopsy cancer biomarker for cancer detection, management and treatment Pending 17-Jan-2023 G01N33/5759
To view Rarecells’s complete patent history, request access »

Rarecells Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rarecells Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Globivest Venture Capital Minority
Manta Capital Advisors Venture Capital Minority
YADAY Family Office Minority
To view Rarecells’s complete investors history, request access »

Rarecells FAQs

  • When was Rarecells founded?

    Rarecells was founded in 2009.

  • Where is Rarecells headquartered?

    Rarecells is headquartered in New York, NY.

  • What is the size of Rarecells?

    Rarecells has 31 total employees.

  • What industry is Rarecells in?

    Rarecells’s primary industry is Diagnostic Equipment.

  • Is Rarecells a private or public company?

    Rarecells is a Private company.

  • What is Rarecells’s current revenue?

    The current revenue for Rarecells is .

  • How much funding has Rarecells raised over time?

    Rarecells has raised $13M.

  • Who are Rarecells’s investors?

    Globivest, Manta Capital Advisors, and YADAY have invested in Rarecells.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process